CSF3
gene geneOn this page
Also known as MGC45931
Summary
CSF3 (colony stimulating factor 3, HGNC:2438) is a protein-coding gene on chromosome 17q21.1, encoding Granulocyte colony-stimulating factor (P09919). Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages.
This gene encodes a member of the IL-6 superfamily of cytokines. The encoded cytokine controls the production, differentiation, and function of granulocytes. Granulocytes are a type of white blood cell that are part of the innate immune response. A modified form of this protein is commonly administered to manage chemotherapy-induced neutropenia. Alternatively spliced transcript variants have been described for this gene.
Source: NCBI Gene 1440 — RefSeq curated summary.
At a glance
- GWAS associations: 37 (top 3% of genes corpus-wide)
- Clinical variants (ClinVar): 29 total
- GTEx eGene: eQTL in 9 tissues, sQTL in 2 (q < 0.05)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.24 (unconstrained)
- MANE Select transcript:
NM_172219 - Interaction hub: 3,056 STRING partners (top 2% of genes corpus-wide)
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:2438 |
| Approved symbol | CSF3 |
| Name | colony stimulating factor 3 |
| Location | 17q21.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MGC45931 |
| Ensembl gene | ENSG00000108342 |
| Ensembl biotype | protein_coding |
| OMIM | 138970 |
| Entrez | 1440 |
Gene structure
Transcript identifiers
Ensembl transcripts: 11 — 8 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay
MANE Select: ENST00000394149
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 4, TSL 2: 1, TSL 3: 2, TSL 4: 1, TSL 5: 1
ENST00000394149, ENST00000225474, ENST00000331769, ENST00000394148, ENST00000479880, ENST00000577675, ENST00000579852, ENST00000582798, ENST00000583218, ENST00000945857, ENST00001143015
RefSeq mRNA: 4 — MANE Select: NM_172219
NM_000759, NM_001178147, NM_172219, NM_172220
CCDS: CCDS11357, CCDS11358, CCDS42314
Canonical transcript exons
ENST00000394149 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000000154 | 40015440 | 40015514 |
| ENSE00001517624 | 40015691 | 40015845 |
| ENSE00003653999 | 40016485 | 40016631 |
| ENSE00003665120 | 40016233 | 40016340 |
| ENSE00003900839 | 40016795 | 40017813 |
Expression profiles
Bgee: expression breadth ubiquitous, 168 present calls, max score 92.15.
FANTOM5 (CAGE): breadth broad, TPM avg 40.4409 / max 2203.3834, expressed in 556 samples.
Highest expression (Bgee): male germ line stem cell (sensu Vertebrata) in testis, olfactory segment of nasal mucosa, type B pancreatic cell, vena cava, olfactory bulb.
Genetic regulation across tissues (GTEx eQTL / sQTL)
CSF3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 9 tissues and its splicing (sQTL) in 2 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
11 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Spleen | eqtl | 1.6e-07 | -0.45 | 17:40021586:A:C |
| Adipose Subcutaneous | eqtl | 9.4e-04 | -0.20 | 17:40032166:C:T |
| Breast Mammary Tissue | eqtl | 1.2e-02 | -0.18 | 17:40021586:A:C |
| Testis | eqtl | 1.3e-02 | +0.28 | 17:39991040:A:G |
| Brain Cortex | eqtl | 1.4e-02 | -0.32 | 17:40796650:T:C |
| Skin Not Sun Exposed Suprapubic | eqtl | 2.2e-02 | +0.47 | 17:39221731:G:A |
| Nerve Tibial | eqtl | 2.3e-02 | +0.26 | 17:40160437:G:A |
| Muscle Skeletal | eqtl | 2.6e-02 | +0.15 | 17:40041162:T:C |
| Brain Hippocampus | eqtl | 3.4e-02 | +0.39 | 17:40166898:T:A |
| Nerve Tibial | sqtl | 4.7e-02 | +1.24 | 17:40807863:GT:G |
| Cells Cultured fibroblasts | sqtl | 4.8e-02 | +0.82 | 17:40449766:GA:G |
FANTOM5 promoters
4 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 160658 | 39.0474 | 526 |
| 160657 | 1.1277 | 207 |
| 160661 | 0.2340 | 123 |
| 160660 | 0.0319 | 9 |
Top tissues by expression
showing 100 of 275 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 92.15 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 91.22 | gold quality |
| type B pancreatic cell | CL:0000169 | 88.66 | gold quality |
| vena cava | UBERON:0004087 | 87.74 | gold quality |
| olfactory bulb | UBERON:0002264 | 87.30 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 85.74 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 84.84 | gold quality |
| triceps brachii | UBERON:0001509 | 84.61 | gold quality |
| gastrocnemius | UBERON:0001388 | 83.73 | gold quality |
| left uterine tube | UBERON:0001303 | 83.42 | gold quality |
| cartilage tissue | UBERON:0002418 | 83.07 | gold quality |
| diaphragm | UBERON:0001103 | 82.71 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 81.24 | gold quality |
| muscle of leg | UBERON:0001383 | 81.02 | gold quality |
| gluteal muscle | UBERON:0002000 | 81.02 | gold quality |
| vastus lateralis | UBERON:0001379 | 80.64 | gold quality |
| muscle organ | UBERON:0001630 | 80.43 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 79.83 | gold quality |
| quadriceps femoris | UBERON:0001377 | 79.61 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 79.26 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 79.09 | gold quality |
| parotid gland | UBERON:0001831 | 78.65 | gold quality |
| right lung | UBERON:0002167 | 78.00 | gold quality |
| upper lobe of lung | UBERON:0008948 | 77.96 | gold quality |
| paraflocculus | UBERON:0005351 | 77.52 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 77.43 | gold quality |
| frontal pole | UBERON:0002795 | 77.40 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 76.64 | gold quality |
| biceps brachii | UBERON:0001507 | 76.52 | gold quality |
| middle frontal gyrus | UBERON:0002702 | 76.44 | gold quality |
| endometrium epithelium | UBERON:0004811 | 76.24 | gold quality |
| mucosa of urinary bladder | UBERON:0001259 | 75.96 | gold quality |
| muscle tissue | UBERON:0002385 | 75.84 | gold quality |
| mucosa of stomach | UBERON:0001199 | 75.41 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 74.88 | gold quality |
| Brodmann (1909) area 10 | UBERON:0013541 | 74.69 | gold quality |
| superficial temporal artery | UBERON:0001614 | 73.81 | silver quality |
| epithelial cell of pancreas | CL:0000083 | 73.73 | gold quality |
| thymus | UBERON:0002370 | 73.36 | gold quality |
| dorsal motor nucleus of vagus nerve | UBERON:0002870 | 73.32 | gold quality |
| inferior olivary complex | UBERON:0002127 | 72.94 | gold quality |
| lung | UBERON:0002048 | 72.88 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 72.16 | gold quality |
| periodontal ligament | UBERON:0008266 | 71.98 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 71.81 | gold quality |
| myocardium | UBERON:0002349 | 71.62 | gold quality |
| deltoid | UBERON:0001476 | 71.33 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 71.22 | gold quality |
| CA1 field of hippocampus | UBERON:0003881 | 71.19 | gold quality |
| gall bladder | UBERON:0002110 | 71.05 | gold quality |
| adenohypophysis | UBERON:0002196 | 70.67 | gold quality |
| cervix epithelium | UBERON:0004801 | 70.66 | gold quality |
| gingival epithelium | UBERON:0001949 | 70.11 | silver quality |
| smooth muscle tissue | UBERON:0001135 | 70.08 | gold quality |
| trachea | UBERON:0003126 | 69.97 | gold quality |
| layer of synovial tissue | UBERON:0007616 | 69.68 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 69.42 | gold quality |
| cerebellar vermis | UBERON:0004720 | 69.15 | gold quality |
| endothelial cell | CL:0000115 | 69.14 | gold quality |
| saphenous vein | UBERON:0007318 | 69.04 | gold quality |
| heart right ventricle | UBERON:0002080 | 68.90 | gold quality |
| male germ cell | CL:0000015 | 68.87 | gold quality |
| omental fat pad | UBERON:0010414 | 68.58 | gold quality |
| peritoneum | UBERON:0002358 | 68.57 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 68.30 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 67.98 | gold quality |
| gingiva | UBERON:0001828 | 67.66 | silver quality |
| caecum | UBERON:0001153 | 67.58 | gold quality |
| vermiform appendix | UBERON:0001154 | 67.55 | gold quality |
| tibia | UBERON:0000979 | 67.20 | gold quality |
| ventral tegmental area | UBERON:0002691 | 67.12 | silver quality |
| epithelium of esophagus | UBERON:0001976 | 67.01 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 66.93 | gold quality |
| sperm | CL:0000019 | 66.80 | gold quality |
| entorhinal cortex | UBERON:0002728 | 66.77 | gold quality |
| tibial artery | UBERON:0007610 | 66.65 | gold quality |
| pericardium | UBERON:0002407 | 66.55 | silver quality |
| popliteal artery | UBERON:0002250 | 66.51 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 66.39 | gold quality |
| endocervix | UBERON:0000458 | 66.10 | gold quality |
| pituitary gland | UBERON:0000007 | 66.05 | gold quality |
| postcentral gyrus | UBERON:0002581 | 66.02 | gold quality |
| orbitofrontal cortex | UBERON:0004167 | 65.89 | gold quality |
| mammalian vulva | UBERON:0000997 | 65.73 | gold quality |
| trigeminal ganglion | UBERON:0001675 | 65.73 | silver quality |
| parietal lobe | UBERON:0001872 | 65.63 | gold quality |
| pons | UBERON:0000988 | 65.37 | silver quality |
| pharyngeal mucosa | UBERON:0000355 | 65.35 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 65.02 | gold quality |
| aorta | UBERON:0000947 | 64.77 | gold quality |
| fallopian tube | UBERON:0003889 | 64.76 | gold quality |
| urinary bladder | UBERON:0001255 | 64.69 | gold quality |
| cardiac atrium | UBERON:0002081 | 64.64 | gold quality |
| seminal vesicle | UBERON:0000998 | 64.62 | silver quality |
| substantia nigra pars reticulata | UBERON:0001966 | 64.26 | gold quality |
| superior surface of tongue | UBERON:0007371 | 64.26 | gold quality |
| lateral globus pallidus | UBERON:0002476 | 64.21 | gold quality |
| uterine cervix | UBERON:0000002 | 64.00 | gold quality |
| inferior vagus X ganglion | UBERON:0005363 | 63.97 | gold quality |
| right atrium auricular region | UBERON:0006631 | 63.95 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-130148 | yes | 4.87 |
| E-HCAD-30 | no | 330.65 |
| E-ANND-3 | no | 0.00 |
HPA expression
RNA tissue specificity: Tissue enhanced
showing 60 of 67 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM |
|---|---|---|
| Urinary bladder | tissue | 53.4 |
| Cervix | tissue | 23.6 |
| Appendix | tissue | 13.4 |
| Pituitary gland | tissue | 10.2 |
| Tongue | tissue | 9.8 |
| Vagina | tissue | 8.4 |
| Adipose tissue | tissue | 8.0 |
| Skeletal muscle | tissue | 6.5 |
| Esophagus | tissue | 5.8 |
| Lung | tissue | 5.3 |
| Olfactory bulb | tissue | 4.3 |
| Cerebellum | tissue | 4.0 |
| Corpus callosum | tissue | 3.9 |
| Cerebral cortex | tissue | 3.7 |
| Retrosplenial and cingulate cortex | tissue | 3.7 |
| Insular cortex | tissue | 3.7 |
| Pancreas | tissue | 3.6 |
| Amygdala | tissue | 3.6 |
| Retrosplenial cortex | tissue | 3.5 |
| Temporal cortex | tissue | 3.5 |
| Basal ganglia | tissue | 3.3 |
| Bone marrow | tissue | 3.3 |
| Ventral forebrain | tissue | 3.2 |
| Occipital cortex | tissue | 3.2 |
| Prefrontal cortex | tissue | 3.1 |
| Hippocampal formation | tissue | 3.1 |
| Entorhinal cortex | tissue | 3.1 |
| Periaqueductal gray | tissue | 3.0 |
| Motor cortex | tissue | 2.9 |
| Somatosensory cortex | tissue | 2.9 |
| Putamen | tissue | 2.8 |
| Septum | tissue | 2.7 |
| Medulla oblongata | tissue | 2.4 |
| Placenta | tissue | 2.4 |
| Spinal cord | tissue | 2.4 |
| Midbrain | tissue | 2.3 |
| Hypothalamus | tissue | 2.3 |
| Substantia nigra | tissue | 2.3 |
| Gallbladder | tissue | 2.1 |
| Endometrium 1 | tissue | 1.9 |
| Thalamus | tissue | 1.9 |
| Superior colliculi | tissue | 1.8 |
| Pons | tissue | 1.7 |
| Smooth muscle | tissue | 1.5 |
| Adrenal gland | tissue | 1.4 |
| Prostate | tissue | 0.9 |
| Locus coeruleus | tissue | 0.7 |
| Hippocampus | tissue | 0.7 |
| Colon | tissue | 0.6 |
| Postcentral gyrus | tissue | 0.6 |
| Rectum | tissue | 0.5 |
| Nucleus accumbens | tissue | 0.5 |
| Choroid plexus | tissue | 0.5 |
| Testis | tissue | 0.4 |
| Tonsil | tissue | 0.4 |
| Lymph node | tissue | 0.3 |
| Retina | tissue | 0.3 |
| Liver | tissue | 0.3 |
| Thymus | tissue | 0.3 |
| Breast | tissue | 0.2 |
Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Blood vessel (11.5), White matter (3.9), Area postrema (3.0), Subiculum (2.9), Ventral hippocampus (2.9).
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): CEBPB, CEBPD, CEBPG, EGR1, FOS, GFI1, HIF1A, HSF1, IRF1, IRF6, JUNB, MXD1, NFKB1, NFKB, POU2F2, PRDM16, RELA, RUNX1, SPI1, STAT3, STAT5A, TCF23, WT1
miRNA regulators (miRDB)
Targeting CSF3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
25 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4692 | 100.00 | 67.32 | 2066 |
| HSA-MIR-4283 | 100.00 | 66.42 | 2097 |
| HSA-MIR-4514 | 99.99 | 67.10 | 1870 |
| HSA-MIR-4447 | 99.85 | 67.81 | 2900 |
| HSA-MIR-3121-3P | 99.82 | 71.96 | 3630 |
| HSA-MIR-3975 | 99.62 | 65.97 | 697 |
| HSA-MIR-6132 | 99.60 | 65.83 | 1554 |
| HSA-MIR-6836-5P | 99.60 | 65.62 | 1538 |
| HSA-MIR-4708-3P | 99.51 | 67.99 | 870 |
| HSA-MIR-6081 | 99.48 | 66.07 | 1446 |
| HSA-MIR-6722-3P | 99.45 | 67.62 | 1919 |
| HSA-MIR-542-3P | 99.34 | 67.58 | 1270 |
| HSA-MIR-532-3P | 99.34 | 65.76 | 1195 |
| HSA-MIR-1264 | 99.25 | 66.81 | 1317 |
| HSA-MIR-6837-5P | 99.25 | 65.47 | 1632 |
| HSA-MIR-4685-5P | 99.25 | 65.99 | 1563 |
| HSA-MIR-2355-5P | 98.83 | 65.51 | 1589 |
| HSA-MIR-935 | 98.82 | 69.36 | 1072 |
| HSA-MIR-4501 | 98.72 | 67.19 | 921 |
| HSA-MIR-4274 | 98.59 | 66.10 | 630 |
| HSA-MIR-3188 | 98.58 | 65.60 | 878 |
| HSA-MIR-2467-5P | 97.36 | 67.71 | 991 |
| HSA-MIR-339-5P | 96.73 | 66.01 | 820 |
| HSA-MIR-3976 | 96.67 | 67.79 | 1187 |
| HSA-MIR-4433B-5P | 95.91 | 66.56 | 727 |
Functional genomics
gnomAD constraint: pLI 4.91e-06, LOEUF 1.24, missense Z 0.934 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000394149 — one region, missense o/e 0.82.
Literature-anchored findings (GeneRIF, showing 40)
- Effect of in vivo infusion of granulocyte colony-stimulating factor on immune function. (PMID:11795665)
- Induces autocrine production of epithelial cell-derived neutrophil attractant-78 in neutrophils. (PMID:11861308)
- effect of recombinant human GCSF on dendritic cell populations in mouse spleen (PMID:11877288)
- G-CSF can induce in vitro and in vivo differentiation of M2 AML t(8;21) cells. (PMID:11920209)
- Stabilizing the native state of recombinant GCSF under physiological conditions using thermodynamic stabilizers, especially high-affinity ligands binding to the native state, inhibits aggregation occurring under structurally nonperturbing conditions. (PMID:12009905)
- G-CSF increases neutrophil function in patients with severe sepsis and septic shock (PMID:12027409)
- expression in airway epithelial cells by interleukin-17 (PMID:12034575)
- Review. The synergy of granulocyte colony-stimulating factor with stem cell factor results in important biologic responses such as the down-regulation of p27kip1 and the independent phosphorylation of STAT3 on tyrosine and serine residues. (PMID:12152985)
- inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. (PMID:12393561)
- Enhanced PMN survival was attributed to effects of epithelial G-CSF and granulocyte-macrophage colony-stimulating factor expression, which inhibit PMN apoptosis.Both CF and normal cells responded to bacteria with increased cytokine production (PMID:12397015)
- results demonstrate that G-CSF is produced in the human follicle shortly before the ovulatory phase and may play an important role in the mechanism of ovulation (PMID:12456601)
- granulocyte colony-stimulating factor decreased platelet-activating factor acetylhydrolase secretion by decidual macrophages (PMID:12548211)
- G-CSF-mediated antiapoptosis is mediated through protein synthesis-dependent mechanisms and involves the Janus kinase-STAT pathway. (PMID:12568301)
- In the presence of ATRA, G-CSF enhanced superoxide release stimulated by the chemotactic peptide, enhanced survival during differentiation, regulated chemotactic peptide receptors CD33 and CD10 but not of CD11b and CD11c. (PMID:12627849)
- Endogenous G-CSF levels in chemotherapy-induced neutropenia are significantly higher than non-chemotherapy related neutropenia and controls. (PMID:12636092)
- The induction of GATA-3, the master transcription factor for a Th2 immune response, can be demonstrated in T cells upon G-CSF treatment in vivo accompanied by an increase of spontaneous IL-4 secretion. G-CSF is a strong immune regulator of T cells. (PMID:12676791)
- tertiary structural perturbations in G-CSF suggest the presence of an intermediate state and possible relation to ligand binding and endocytic trafficking (PMID:12717025)
- Conformation change of an epitope of the granulocyte-colony stimulating factor after binding to receptors. (PMID:12946100)
- TNF, GM-CSF, and G-CSF induce actin depolymerization and morphological changes through activation of ERK and/or p38 MAPK, and cytokine-induced actin reorganization may affect inhibitory effect of these cytokines on neutrophil chemotaxis. (PMID:12954601)
- G-CSF expression in some bladder cancers appears to be an early event during malignant transformation that increases beta1-integrin expression and adhesion and thereby may promote tissue invasion. (PMID:14751388)
- significant associations of endogenous G-CSF levels with inflammatory mediators early in the development of severe lung injury suggest an endogenous anti-inflammatory role of G-CSF in vivo (PMID:14769149)
- The significantly higher level of G-CSF in follicular fluid (FF) than in serum and the expression of G-CSF and its receptor in FF by granulosa cells suggest an important role for this growth factor in ovarian function. (PMID:15019810)
- G-CSF appears to be a suppressor of antitumor immunity (PMID:15214947)
- G-CSF is associated with the expression of proliferation vascularization in memingioma. (PMID:15218949)
- The G-CFS may provide clinically useful information, particularly regarding prognosis and response to treatment. (PMID:15576295)
- G-CSF, a promoter of tolerogenic dendritic cells, may be evaluated for the treatment of human type 1 diabetes (PMID:15616013)
- Serum G-CSF levels in 70.4% (38 of 54 cases) of the chronic aplastic anemiapatients were increased (272.76 +/- 58.39ng/L) (PMID:15622763)
- one of the major roles of Stat3 in the G-CSF signaling pathway is to augment the function of C/EBPalpha, which is essential for myeloid differentiation (PMID:15664994)
- osteoblast activity, as measured by histomorphometry and osteocalcin expression, is strongly down-regulated during G-CSF treatment (PMID:16037394)
- Correlation between endogenous G-CSF and CD34(+) cell levels supports the administration of G-CSF as an option for regeneration of myocardial tissue after acute myocardial infarct. (PMID:16051386)
- Protein kinase C plays a role in activation of granulocyte-colony stimulating factor in lung cancer. (PMID:16211258)
- crystal structure of the signaling complex between human granulocyte colony-stimulating factor (GCSF) and a ligand binding region of GCSF receptor (GCSF-R), has been determined to 2.8 A resolution (PMID:16492764)
- PAR2-driven upregulation of VCAM-1 cell surface expression and the release of IL-8 and G-CSF from bronchial fibroblasts may be important in promoting neutrophilic airways inflammation. (PMID:16498082)
- monocytes mobilized into the blood by G-CSF or AMD3100 stimulate angiogenesis at sites of ischemia through a paracrine mechanism (PMID:16735597)
- It appears that G-CSF mobilizes more CD34(+) cells, mature Dendritic cellswithin the same donor than does GM-CSF. (PMID:16822885)
- A progression-promoting effect of G-CSF and GM-CSF in human head and neck squamous cell carcinomas. (PMID:16912178)
- G-CSF has a role in the induction of E-selectin ligands on myeloid cells, thus providing mechanistic insight into the pathobiology of G-CSF complications (PMID:16980970)
- The observed up-regulation of G-CSF points towards a role in the pathophysiology of human ischemic stroke. (PMID:17047971)
- A comparison of the relative rates of oxidation of methionine residues in short peptides with those of corresponding methionine residues in recombinant human G-CSF yields an understanding of how protein tertiary structure affects oxidation reactions. (PMID:17176065)
- G-CSF and GM-CSF might accelerate tumor progression by directly regulating COX-2 expression, independently of an autocrine mechanism. (PMID:17342342)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | csf3b | ENSDARG00000098752 |
| danio_rerio | csf3a | ENSDARG00000102211 |
| mus_musculus | Csf3 | ENSMUSG00000038067 |
| rattus_norvegicus | Csf3 | ENSRNOG00000008525 |
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1339751) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 10 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| decreased neutrophil cell number | 2 |
| decreased leukocyte cell number | 1 |
| decreased monocyte cell number | 1 |
| impaired myelopoiesis | 1 |
| increased susceptibility to bacterial infection | 1 |
| abnormal neutrophil physiology | 1 |
| increased hematocrit | 1 |
| increased circulating alanine transaminase level | 1 |
| decreased eosinophil cell number | 1 |
| increased lymphocyte cell number | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Bos taurus | P35833 | 95.4% | Diamond |
| Ovis aries | Q28746 | 95.4% | Diamond |
| Felis catus | O02708 | 91.3% | Diamond |
| Canis lupus familiaris | P35834 | 91.3% | Diamond |
| Sus scrofa | O02837 | 87.9% | Diamond |
| Gallus gallus | P13854 | 41.2% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| MIR6884 | ncRNA | 102466757 |
| THRA | protein-coding | 7067 |
| NR1D1 | protein-coding | 9572 |
| MED24 | protein-coding | 9862 |
| SNORD124 | snoRNA | 101340251 |
| PSMD3-AS1 | ncRNA | 139432819 |
| LRRC3C | protein-coding | 100505591 |
| GSDMA | protein-coding | 284110 |
| PSMD3 | protein-coding | 5709 |
Protein
Protein identifiers
Granulocyte colony-stimulating factor — P09919 (reviewed: P09919)
Alternative names: Pluripoietin
All UniProt accessions (6): P09919, J3KTH8, J3QRD4, J3QRX2, Q6FH65, Q8N4W3
UniProt curated annotations — full annotation on UniProt →
Function. Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes.
Subunit / interactions. Monomer.
Subcellular location. Secreted.
Post-translational modifications. O-glycan consists of Gal-GalNAc disaccharide which can be modified with up to two sialic acid residues (done in recombinantly expressed G-CSF from CHO cells).
Similarity. Belongs to the IL-6 superfamily.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| P09919-1 | Long | yes |
| P09919-2 | Short | |
| P09919-3 | 3 |
RefSeq proteins (4): NP_000750, NP_001171618, NP_757373, NP_757374 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR009079 | 4_helix_cytokine-like_core | Homologous_superfamily |
| IPR030473 | IL6/GCSF/MGF_CS | Conserved_site |
| IPR030474 | IL-6/GCSF/MGF | Family |
| IPR040117 | GCSF/MGF | Family |
Pfam: PF16647
UniProt features (23 total): helix 9, turn 3, strand 2, disulfide bond 2, splice variant 2, sequence variant 2, signal peptide 1, chain 1, glycosylation site 1
Structure
Experimental structures (PDB)
7 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 5GW9 | Crystal structure of C163, a backbone circularized G-CSF | X-RAY DIFFRACTION | 1.65 |
| 5ZO6 | Crystal structure of C166, a backbone circularized G-CSF | X-RAY DIFFRACTION | 1.7 |
| 1RHG | THE STRUCTURE OF GRANULOCYTE-COLONY-STIMULATING FACTOR AND ITS RELATIONSHIP TO THOSE OF … | X-RAY DIFFRACTION | 2.2 |
| 1CD9 | 2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR | X-RAY DIFFRACTION | 2.8 |
| 2D9Q | Crystal Structure of the Human GCSF-Receptor Signaling Complex | X-RAY DIFFRACTION | 2.8 |
| 1PGR | 2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR | X-RAY DIFFRACTION | 3.5 |
| 1GNC | STRUCTURE AND DYNAMICS OF THE HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR DETERMINED BY … | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P09919-F1 | 84.67 | 0.56 |
Human Protein Atlas
Protein class: Predicted secreted proteins, Plasma proteins, Cancer-related genes, Candidate cancer biomarkers
Protein evidence: Evidence at protein level
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Disulfide bonds (2)
| Type | Positions |
|---|---|
| Disulfide bond | 69–75, 97–107 |
Glycosylation sites (1)
| Type | Positions |
|---|---|
| O-linked (galnac…) threonine | 166 |
Function
Pathways and Gene Ontology
Reactome pathways
3 curated (TAS) of 8; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
8 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-9968734 | Differentiation of Circulating Monocytes | curated |
| R-HSA-6783783 | Interleukin-10 signaling | curated |
| R-HSA-449836 | Other interleukin signaling | curated |
| R-HSA-1280215 | Cytokine Signaling in Immune system | — |
| R-HSA-168256 | Immune System | — |
| R-HSA-9705462 | Inactivation of CSF3 (G-CSF) signaling | electronic |
| R-HSA-9674555 | Signaling by CSF3 (G-CSF) | electronic |
| R-HSA-449147 | Signaling by Interleukins | — |
MSigDB gene sets: 298 (showing top):
GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_NK_CELL_VS_CD11B_DC_DN, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, MODULE_92, AP1_01, GOBP_RESPONSE_TO_ETHANOL, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, MODULE_64, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOMF_GROWTH_FACTOR_ACTIVITY, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION
GO Biological Process (15): immune response (GO:0006955), positive regulation of cell population proliferation (GO:0008284), cytokine-mediated signaling pathway (GO:0019221), macrophage differentiation (GO:0030225), positive regulation of actin filament polymerization (GO:0030838), granulocyte differentiation (GO:0030851), granulocyte colony-stimulating factor signaling pathway (GO:0038158), response to ethanol (GO:0045471), positive regulation of myeloid cell differentiation (GO:0045639), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), cellular response to lipopolysaccharide (GO:0071222), cellular response to cytokine stimulus (GO:0071345), regulation of actin filament organization (GO:0110053), signal transduction (GO:0007165)
GO Molecular Function (6): cytokine activity (GO:0005125), granulocyte colony-stimulating factor receptor binding (GO:0005130), growth factor activity (GO:0008083), enzyme binding (GO:0019899), signaling receptor binding (GO:0005102), protein binding (GO:0005515)
GO Cellular Component (3): extracellular region (GO:0005576), lysosomal lumen (GO:0043202), endocytic vesicle lumen (GO:0071682)
Reactome top-level categories
5 top-level categories:
| Category | Pathways |
|---|---|
| Signaling by Interleukins | 2 |
| Cytokine Signaling in Immune system | 2 |
| Signaling by CSF3 (G-CSF) | 1 |
| Developmental Cell Lineages | 1 |
| Immune System | 1 |
GO top-level categories
48 GO namespaces:
| Category | Terms |
|---|---|
| myeloid leukocyte differentiation | 2 |
| receptor ligand activity | 2 |
| protein binding | 2 |
| immune system process | 1 |
| response to stimulus | 1 |
| cell population proliferation | 1 |
| regulation of cell population proliferation | 1 |
| positive regulation of cellular process | 1 |
| cell surface receptor signaling pathway | 1 |
| cellular response to cytokine stimulus | 1 |
| mononuclear cell differentiation | 1 |
| actin filament polymerization | 1 |
| regulation of actin filament polymerization | 1 |
| positive regulation of protein polymerization | 1 |
| positive regulation of cytoskeleton organization | 1 |
| positive regulation of supramolecular fiber organization | 1 |
| cytokine-mediated signaling pathway | 1 |
| response to alcohol | 1 |
| myeloid cell differentiation | 1 |
| positive regulation of cell differentiation | 1 |
| regulation of myeloid cell differentiation | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| transcription by RNA polymerase II | 1 |
| positive regulation of DNA-templated transcription | 1 |
| phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1 |
| regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1 |
| positive regulation of intracellular signal transduction | 1 |
| response to lipopolysaccharide | 1 |
| cellular response to molecule of bacterial origin | 1 |
| cellular response to lipid | 1 |
| cellular response to oxygen-containing compound | 1 |
| response to cytokine | 1 |
| actin filament organization | 1 |
| regulation of actin cytoskeleton organization | 1 |
| regulation of supramolecular fiber organization | 1 |
| cell communication | 1 |
| cellular process | 1 |
| signaling | 1 |
| regulation of cellular process | 1 |
| cellular response to stimulus | 1 |
| cytokine receptor binding | 1 |
| growth factor receptor binding | 1 |
| binding | 1 |
| cellular anatomical structure | 1 |
| lysosome | 1 |
| vacuolar lumen | 1 |
| endocytic vesicle | 1 |
| intracellular organelle lumen | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 8 of 25 annotations. The rest are phylogenetic / computational / electronic (IEA).
8 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| cellular response to cytokine stimulus | BP | direct assay |
| granulocyte colony-stimulating factor signaling pathway | BP | direct assay |
| positive regulation of actin filament polymerization | BP | direct assay |
| positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | BP | direct assay |
| positive regulation of transcription by RNA polymerase II | BP | direct assay |
| regulation of actin filament organization | BP | direct assay |
| cytokine activity | MF | direct assay |
| enzyme binding | MF | physical interaction |
Protein interactions and networks
STRING
showing 15 of 3,056 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CSF3 | CSF2 | P04141 | 942 |
| CSF3 | CD34 | P28906 | 942 |
| CSF3 | IL6 | P05231 | 936 |
| CSF3 | IL3 | P08700 | 924 |
| CSF3 | CSF3R | Q99062 | 920 |
| CSF3 | IL1B | P01584 | 918 |
| CSF3 | IL17A | Q16552 | 912 |
| CSF3 | IFNG | P01579 | 904 |
| CSF3 | TNF | P01375 | 900 |
| CSF3 | CXCL8 | P10145 | 898 |
| CSF3 | CCL2 | P13500 | 883 |
| CSF3 | CCL3 | P10147 | 881 |
| CSF3 | IL10 | P22301 | 873 |
| CSF3 | IL7 | P13232 | 869 |
| CSF3 | CXCL1 | P09341 | 865 |
IntAct
Human interaction partners of CSF3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
1 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| PTPRG | association | 0.350 | 1 |
BioGRID (12 interactions; top human partners by supporting records): AHNAK2 (Affinity Capture-MS), COL14A1 (Affinity Capture-MS), MYO18A (Affinity Capture-MS), NRN1 (Affinity Capture-MS), PARVG (Two-hybrid), PTPRG (Affinity Capture-MS), PTPRJ (Affinity Capture-MS), S100A6 (Reconstituted Complex), S100P (Reconstituted Complex), SCARB1 (Affinity Capture-MS), TBX3 (Two-hybrid), TRRAP (Affinity Capture-MS)
SIGNOR signaling
3 signaling interactions:
| A | Effect | B | Mechanism |
|---|---|---|---|
| CSF3 | up-regulates | CSF3R | binding |
| CSF3 | up-regulates | CSF2RA | binding |
| CSF3 | up-regulates | Angiogenesis |
Protein complexes (CORUM) (1)
Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).
1 complexes by size:
| Complex | Subunits | Members |
|---|---|---|
| ★ CSF3-CSF3R complex | 2 | CSF3, CSF3R |
Ligand–receptor pairs (CellPhoneDB) (1)
Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.
1 ligand–receptor pairs:
| Partner | This gene’s role | Signaling class |
|---|---|---|
| CSF3R | ligand | Signaling by Colony-Stimulating factor |
Disease & clinical
Genetic variants
Variant evidence for CSF3: 29 ClinVar records (0 pathogenic / likely pathogenic); 37 GWAS associations.
ClinVar
29 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 20 |
| Likely benign | 0 |
| Benign | 6 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 35 predictions of 204):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 17:40015846–40015847 | donor_loss | 1.0000 | 5 |
| 17:40016231–40016232 | acceptor_loss | 1.0000 | 5 |
| 17:40016341–40016342 | donor_loss | 1.0000 | 4 |
| 17:40016353 | donor_gain | 1.0000 | |
| 17:40016483–40016484 | acceptor_loss | 1.0000 | 6 |
| 17:40016632–40016633 | donor_loss | 1.0000 | 5 |
| 17:40015515–40015516 | donor_loss | 0.9900 | 5 |
| 17:40016226 | acceptor_gain | 0.9900 | |
| 17:40016341 | donor_loss | 0.9900 | |
| 17:40016793 | acceptor_loss | 0.9900 | 2 |
AlphaMissense
210 missense substitutions predicted likely pathogenic (of 1,301 scored), across 72 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| F177 | 8 | 0.886 | 0.977 |
| D142 | 8 | 0.767 | 0.869 |
| C75 | 7 | 0.892 | 0.939 |
| F43 | 7 | 0.857 | 0.960 |
| C107 | 7 | 0.807 | 0.903 |
| C97 | 7 | 0.795 | 0.871 |
| E79 | 7 | 0.762 | 0.842 |
| C69 | 6 | 0.807 | 0.870 |
| F193 | 5 | 0.908 | 0.926 |
| F173 | 5 | 0.809 | 0.851 |
| K53 | 5 | 0.745 | 0.855 |
| F146 | 5 | 0.727 | 0.908 |
| D145 | 5 | 0.671 | 0.742 |
| G183 | 4 | 0.828 | 0.854 |
| M154 | 4 | 0.768 | 0.793 |
| C47 | 4 | 0.742 | 0.875 |
| G114 | 4 | 0.732 | 0.848 |
| E49 | 4 | 0.702 | 0.759 |
| L115 | 3 | 0.895 | 0.907 |
| I89 | 3 | 0.862 | 0.949 |
HPA cancer prognostics
RNA cancer specificity: Cancer enhanced (Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma)
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
1 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Glioblastoma Multiforme (validation) | unfavorable | 6.96e-05 |
Disease associations
OMIM: gene MIM:138970 | disease phenotypes:
GWAS associations
showing 30 of 37 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST004626_8 | Myeloid white cell count | 6e-191 |
| GCST90002407_625 | White blood cell count | 8e-133 |
| GCST008916_121 | Asthma | 2e-62 |
| GCST005973_8 | White blood cell count | 9e-62 |
| GCST001137_10 | White blood cell count | 9e-35 |
| GCST001137_8 | White blood cell count | 2e-31 |
| GCST90002398_312 | Neutrophil count | 1e-23 |
| GCST002557_5 | Neutrophil count | 3e-23 |
| GCST90002399_324 | Neutrophil percentage of white cells | 8e-21 |
| GCST90002398_311 | Neutrophil count | 1e-18 |
| GCST90002407_627 | White blood cell count | 1e-18 |
| GCST004613_34 | Sum neutrophil eosinophil counts | 1e-17 |
| GCST90002389_100 | Lymphocyte percentage of white cells | 1e-17 |
| GCST004614_8 | Granulocyte count | 2e-17 |
| GCST004620_20 | Sum basophil neutrophil counts | 6e-17 |
| GCST004629_151 | Neutrophil count | 6e-17 |
| GCST001134_16 | White blood cell types | 4e-16 |
| GCST004626_9 | Myeloid white cell count | 4e-16 |
| GCST000589_2 | White blood cell count | 3e-14 |
| GCST004633_5 | Neutrophil percentage of white cells | 1e-13 |
| GCST006959_49 | Rheumatoid arthritis | 3e-13 |
| GCST008916_86 | Asthma | 6e-13 |
| GCST004608_199 | Granulocyte percentage of myeloid white cells | 8e-13 |
| GCST002318_48 | Rheumatoid arthritis | 2e-12 |
| GCST008916_5 | Asthma | 2e-12 |
| GCST004632_19 | Lymphocyte percentage of white cells | 6e-12 |
| GCST004610_2 | White blood cell count | 1e-11 |
| GCST004128_2 | White blood cell count (neutrophil) | 5e-11 |
| GCST004126_2 | White blood cell count | 9e-11 |
| GCST002557_6 | Neutrophil count | 1e-10 |
EFO canonical traits (from GWAS)
9 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0004833 | neutrophil count |
| EFO:0007997 | granulocyte percentage of myeloid white cells |
| EFO:0004842 | eosinophil count |
| EFO:0007987 | granulocyte count |
| EFO:0005090 | basophil count |
| EFO:0007993 | lymphocyte percentage of leukocytes |
| EFO:0007990 | neutrophil percentage of leukocytes |
| EFO:0004534 | creatine kinase measurement |
| EFO:0006312 | mitochondrial DNA measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
111 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Particulate Matter | decreases reaction, affects expression, decreases secretion, affects cotreatment, decreases expression (+5 more) | 8 |
| Lipopolysaccharides | increases expression, affects cotreatment, decreases reaction, increases secretion | 5 |
| Estradiol | affects expression, affects cotreatment, increases expression | 4 |
| Tretinoin | decreases reaction, decreases uptake, increases expression, increases reaction, decreases expression | 4 |
| nickel chloride | affects cotreatment, increases secretion, increases expression, increases reaction | 3 |
| Vehicle Emissions | increases abundance, increases expression, affects expression, affects cotreatment, decreases abundance (+1 more) | 3 |
| Cannabidiol | decreases reaction, increases expression | 3 |
| Dust | decreases expression, increases expression, increases secretion | 3 |
| Silicon Dioxide | increases secretion, increases expression | 3 |
| Tobacco Smoke Pollution | affects expression, increases expression, increases secretion | 3 |
| Asbestos, Crocidolite | increases secretion, decreases reaction, increases expression | 3 |
| titanium dioxide | affects binding, increases secretion, affects expression | 2 |
| sodium arsenite | increases expression | 2 |
| 3,4,5,3’,4’-pentachlorobiphenyl | increases expression | 2 |
| Resveratrol | decreases reaction, increases expression | 2 |
| Arsenic Trioxide | decreases uptake, increases expression, increases response to substance, increases reaction, increases uptake (+1 more) | 2 |
| Air Pollutants | increases abundance, increases expression | 2 |
| Benzo(a)pyrene | increases expression, affects methylation | 2 |
| Endosulfan | decreases expression, increases expression | 2 |
| Tetradecanoylphorbol Acetate | affects cotreatment, increases expression, affects expression | 2 |
| Asbestos, Serpentine | increases expression, increases secretion | 2 |
| Silver Compounds | increases secretion, affects cotreatment, increases expression, affects binding | 2 |
| Cadmium Chloride | increases expression | 2 |
| Interleukin 1 Receptor Antagonist Protein | decreases reaction, increases secretion, decreases secretion | 2 |
| Glupearl 19S | increases expression | 1 |
| sotorasib | affects cotreatment, decreases expression | 1 |
| TL8-506 | increases expression, affects cotreatment | 1 |
| 7-ketocholesterol | increases expression, decreases reaction | 1 |
| 2-anisidine | affects expression | 1 |
| propionaldehyde | increases expression | 1 |
Cellosaurus cell lines
4 cell lines: 2 finite cell line, 1 spontaneously immortalized cell line, 1 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_6G75 | IA1-7 | Spontaneously immortalized cell line | Female |
| CVCL_B0ZB | Abcam K-562 CSF3 KO | Cancer cell line | Female |
| CVCL_B6BP | MSC G-CSF#1 | Finite cell line | Male |
| CVCL_B6BQ | MSC G-CSF#2 | Finite cell line | Male |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.